Why Skittles, Cheez-Its and other snacks could get more expensive with this $36 billion merger

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results, leading to a more than 17% drop in shares during early trading on Tuesday, despite the results not being poor overall. The negative investor reaction stemmed from two disappointing developments in its pipeline, which may present buying opportunities for some investors. Want More Context? 🔎

Firefly Aerospace (NASDAQ: FLY) debuted on the Nasdaq exchange on Thursday at $45, experiencing a significant rise of 34.1% to close at $60.35. However, on Friday, the company retained some gains but saw a notable decline from its initial surge. Want More Context? 🔎

Alpha Metallurgical Resources (NYSE:AMR) reported second quarter 2025 results with an adjusted EBITDA of $46.1 million from 3.9 million tons shipped, achieving a $10 per ton reduction in coal sales costs. The company improved liquidity to $557 million, restarted its share buyback program, and lowered its cost guidance, highlighting operational efficiency amidst declining met coal prices. Want More Context? 🔎

Bicycle Therapeutics Plc (NASDAQ:BCYC) reported Q2 2025 GAAP revenue of $2.9 million, significantly below the $9.43 million analyst estimate, while net loss per share widened to $(1.14), surpassing the $(0.95) forecast. Despite increased clinical investment and operational spending aimed at advancing its pipeline of precision-guided therapeutics using its proprietary Bicycle molecule platform, the company emphasized the need for operational discipline and clear milestones ahead. Want More Context? 🔎

Warren Buffett will step down as CEO of Berkshire Hathaway at the end of the year but will remain as chairman and likely maintain communication with incoming CEO Greg Abel. Despite being a net seller of stocks for 11 quarters, Buffett continues to find some of his previous investment picks attractive and still makes selective purchases. Want More Context? 🔎

DocGo (NASDAQ:DCGO) reported a Q2 2025 revenue of $80.4 million, surpassing estimates but reflecting a decline due to the exit from high-margin contracts, resulting in a net loss of $13.3 million. Despite reduced profitability, management reaffirmed full-year guidance and reported increased cash balances of $128.7 million, as they focus on expanding transportation and payer/provider partnerships. Want More Context? 🔎